STAT+: What to watch at ESMO: readouts from trials in lung, prostate, and other types of cancer
Europe’s major cancer research conference kicks off in Madrid on Friday, with headline — and potentially practice-changing — readouts from trials in lung, prostate, and other types of cancer.
STAT will be reporting from the annual meeting of the European Society for Medical Oncology through Monday. Here are just a few of the presentations we’ll be keeping an eye on at this year’s conference.
The Rybrevant relay
Not even a month ago, Johnson & Johnson announced that a combination of its antibody Rybrevant with lazertinib hit its endpoint in a first-line non-small cell lung cancer trial, outperforming the current standard treatment, AstraZeneca’s Tagrisso. Now, the full data, which apply to tumors that have EGFR mutations, are being presented in a prime spot Monday afternoon.
